Millennium kept at market perform by JMP

JMP Securities analyst Charles C. Duncan maintained Millennium Pharmaceuticals, Inc. at market perform after the company reported third-quarter results that came in below expectations with Velcade sales, the stock's main driver, lower on a sequential basis. JMP said it is focused on lowered Velcade sales expectations for fiscal 2006 to $220 million from a range of $225-$250 million. Shares of the Cambridge, Mass.-based pharmaceutical company were up 60 cents, or 5.36%, at $11.79. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.